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logic blood plopertlas 8s indicated by plasma fibnnogen levels (FIB) and left 
ventrieular (LV) function after myocardial infarction (MI) remain underlain. 
Met t '~:  92 patients (pta) with proven anterior MI were investigated. NO 
inten~ntlonal or thrombolylic therapy was performed. Inclusion cntena were: 
1. Ilmtatad proximal occlusion of the kPft amOrlOr descending arfery (LAD) :,3 
weeks af1~ MI. 2, Remaining corona~/allerles and corresl:~Ondtng LV wall 
segmenl~ ~m nom~l. PI~. were ~ into 4 gro~ (gr.): 
gro~e PAP (~1 ~k)  F~B 
Re~lmfl~; Tbe 4 gr, were o:~mpafable regarding age, gender, age el MI and 
nsk fe¢toe~ Pts. m gf. 3 and 4 ~ more frequent ACE inh~bitom than gr. 
1 and 2 pts. LV eiect~ fraction (EF) deemase~ and the number 0! akinet~ 
~ ! S  (aS) ~.vea~ed from gr. ~ to4~ 
group l 2 3 4 
FIB (~)  2~03 ,tOt O" 2885 4187" 
(%) 6o.0 SO.a" S3:' ~. t "  
AS (%) S,~8 a3.a-- ~.7 ~.5-- 
2 p ~ O0~, g~. !~4:  p < O00~ 
Conci~u~: PAP has e ~ ~leet on ~ LV.func~on after ~qten(~" 
MI d~to  I ~  oedlJ~on of the L~D, I ~  by #~ d e ~  
of o~,)ary collatera~. This is a~,~ed by u~avomabee meofo~c blood 
i-..~p~,i:4is as indicated by ~ FiB ~ s .  Pts. without PAP and 
elevated FiB levets m at I ~  dsk for a targe MI and reduced LV-functon. 
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11004-1311 An~iotensin Converting Enzyme Inhibitor 
CaptopHI Does not  Improve Emrdse  Tolerance 
or  Reduce Exercise Induced Myocardial  
Ischemia in Patients With Anoina Pec lods  
U. Thadani, N. B~ar. Urmmrsil), of Oldahoma, Oklahoma Cd~. OK. USA 
Angiotensin is a potent coronary vasoconstnctor but reported effects of con- 
vetting enzyme inhib~Drs On exercise reduced myocardial ischemia am con- 
flicting. In a double-blind, ral~0mized crossover study, effects of ~ing~e oral 
doses of placebo, Captoprt| (CAPT) 25 mg and CAPT SO mg were eve~u- 
ated in 15 patients wdh exercise induced angina assemated with __.1 mm ST 
depmssioe. All antianginal o~ugs were discontinued and patmnts performed 
symptom limited treadmill exercise tests on 3 separate days before and I a~l 
4 hours after the administrations of the study drug. Compared to pre-drug 
baseline values, mean changes in seconds at t and 4 hours (h) post~Jose 
for various exercise variables were: 
Placebo CAPT 25 mg .... CAPT 25 mg 
th 4h lh  411 lh  4h 
Time to Angina +20 +5 + 1 - 6 +6 - 1 
Total Exerc-"~e "~me +1 -4 +8 -6 *6 -8 
"i~me tO t •rn ST ~ +8 -1 +14 +26 +21 +7 
Data show lack of improvement in exercise times or p.'olongation of time 
to myocardial ischemia after the two doses of CAPT compared to placebo. 
Above results were confirmed in another group of 27 patients who received 
CAPT 25 mg tid for 2 weeks followed by CAPT 50 mg tid for 4 weeks. These 
results suggest lhat CAPT does not exert any antianginal or anti-ischemic 
effects in patients with exercise induced angina. 
1004-1321 Angiotens in  II Receptor Antagonism Does Not 
Prevent Tolerance to Cont inuous Transdermal 
Nitroglycerin 
S.D. Milone, E.R. Azevedo, A.B. Parker, C. Forster, J.D. Parker. Universi~ 
of Toronto, Canada 
Background: Animal data suggests that nitrate tolerance may be caused by 
increased supemxtde an~ preduct~ and may be prevented w~ an ang~o, 
tensin II receptor (ATo antagar, st. We teared the h vpothas=s that tt~wapy 
with the ATt antagonist Lossflan wo~ld prevent he (~elopm~t of romance 
to cominuoua trfnsdermat nitr0glyeenn (TGTN) in humans. 
Method: Twemy normal mato vofur~e~m rece~ve~ Losa~an 75 rn~0ay 
or placebo in a ~ e ~ ,  double t~ind, pare, el ~ ,  A~,  I 
contlmmus TGTN 0,0 m0/hr wa~, glv~1 m ~tit lon to Losahan Of 
to ~11 v~lL.mt~r~. Standing SBP and e~upm~ fof~.asm ~ d i ~  
measumm~ta w~m ewlua~ and I~mmto¢~ was ~ as em m~l  
of p~asma vokm~e, Measurem~t~ were ma~e ~t ~ e ,  3 ~u~ foeow~ 
acute TGTN and 1 week after therapy with the ~t ton  of L0ea~m On= 
ptaee:be) ~nd "rGTN. 
Reeutt~'/leutaly, TGTN c~,~ a fall in SBP m both gr0tq~, Fo~,a~g 
sustain~ TGTN therapy, SBP was uret~lged from baseline m bath 
(Lo88d~n: 117 ~ 11 vs 111 -t 15 m~Hg; Placebo: 11"/' ± 11 w 115 ~ 12 
mmHg). Tolerance also ~ to 1he forearm venous r e ~  and 
not prevente~l by Lo~rfan 
Pm YGI'N Post ~ta~ TGTN 
L~sanan 070 ± 020" 025 • 023" 
' p.  0 05 vemus pm.,SLGTN ~p ~ 001 versus I~e-TGTN 
Hemato~tt decreased after acute TGTN and remained s ign i~t ly  dl. 
minished folk~mg suslamed TGTN therapy in both groups. 
Conc/u~on: Therapy wffh an angmlensin n ~or  antagonist ~ not 
prevent he devalo~ment m tolerarce tO the hemodynam¢ and venous ~ 
of TGTN. 
[loo.:1 1 =, 
Fill ing ~ure  aml ~ma Hormones for 
Advanced Progressive Remodel ing ~ Effect of  
Quinapdl  
I. Kugler, P. Gaudron, K. Hu, W. Bauer, C. Eilles, G. ErtL 2 ~ Medica/Clinic, 
Un~ver~y of Heidelberg at Mannheim, Germany 
B a ~  Progressive left vehicular (LV) ralatmn after myeeardml m- 
farclmn (MI) and h~gh norepmephnne in LV dysfunction cam/an adverse 
pro~-~o.31s. Our hypotl'te~s was that pmvefll]on of repetitwe rise of filling 
pressure and of plasma homlones during ordinary dmly mmrcme may be 
,mportant for pmvan~on of fu~er remodeling alter mfamtlon. 
MeU~ods: 25 pa1~mts with pmgresswe remodeling ware randomized (dou- 
ble-blied) to placebo (P, n = 13) or qufnapnl (Q. 10-40 mojday, n = 12). At 
baseline and follow-up (1, 6 and 12 months (M)) LV end-diastolic volume 
index (EDV1. ml/rn 2, gated SPECT), h o ~  (ANP, RIA. RTml; Nore- 
p~nephnne, HPLC, Wml) and LV titling pressure at rest and dunng I~cycte 
exerose equwalent vo dairy ordinary acbvmes (Swan-Ganz-catheter) were 
measureD. 
Resu/ts: LV dilation continued on P (della EDVI 6 M: 9 ± 2.2; 12 M: 26 
± 2.2) but not on Q (b M: 0.1 ± 2.5, 12 M I ± 2.5). Rme of wedge p~e-~ure 
with exerose dld not differ at baseline (Q: 20 ± 2, P: 21 ± 3) but was lower 
on Q (17 ± 1") compared to P (24 ± 5) at 12 M. At rest NOR decreased in 
O (322 ± 37. 420 ± 58, 238 ± 42, 270 ± 29 t , rANOVA p < 0.05 ,,Is 1 M) 
but not on P (331 ± 44. 422 ± 61,235 ± 31,284 ± 54). Rise of NOR on 
ese~se .=t 12 mo~ths was alleviated by O (baseline: 776 ± 103. 12 M: 476 
± 81. p < 0.05) compared to baseline, not on P (has.ins: 742 ± 157, 12 M: 
498 ± 101, n.s.). 
Conclusion: Prevention of further remodeling by O may be due to affen- 
uation of exercme induced rise of filling pressure and of exerose induced 
neurohumoral activahon (mean ± SEM; "p < 0.05 vs P). Thus, reduction of 
repetitive nse of filling pressure dunng dally ordinary activity may be tmpertant 
for prevention of progression of LV dilation by quinapnL 
I 1004-1341 Recovery of Myocyte Hypert rophy and Slippage 
Associated With the Left Vsntrtcumr Remodeling 
of  Myocardial Hibernation 
T. Lai, L Me, W.-C. Wu. D. Knibbs. D. Waters. C. Chen. Hartford Ho,~piral. 
Hartford. Connechcut. USA 
We have previously shown that LV remodeling occurs in hibernating my. 
ocardium (HM), with wall thinning related to slipaage of my0cyte bundles and 
myocyle hypertrophy. To study whether repedusion reverses these cellular 
changes, we created a LAD stenosis to reduce flow by ~ 4~ m 5 p~gs. 
producing severe regional LV dysfunction. At 7 days LV bi~p.~i=s were taken 
from the hibernating and normal regions; then the stenoses were released 
to reperfuse the HM and pigs were kept alive tar 4 weeks for recover. Con- 
trois consisted of 4 sham-operated pigs without stenoses. The number of 
myocytes per mm thickness of LV walt was counted and expressed as cell 
